Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miglustat in Spastic Paraplegia 11
NCT04768166Phase 2Completed
- Sponsor
- IRCCS Fondazione Stella Maris
- Start
- Jun 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of miglustat in hereditary spastic paraplegia type 11 (HSP11), sponsored by IRCCS Fondazione Stella Maris. Started Jun 2021; status: completed.
02
Drugs
miglustat
03
Conditions
hereditary spastic paraplegia type 11 (HSP11)
Beyond the preview
Go deeper on NCT04768166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04768166.